Propanc releases preclinical PDAC data for PRP, eyes 2027 trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Propanc releases preclinical PDAC data for PRP, eyes 2027 trial

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

September 22, 2026 8:30 AM EDT

New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erascas Phase 1 ERAS-0015 Dataset

MELBOURNE, Australia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (Propanc or the Company), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of lead candidate PRP against recently reported clinical datasets from Erasca, Inc.s pan-RAS molecular glue ERAS-0015 in pancreatic ductal adenocarcinoma (PDAC).

The analysis follows FDA approval of Revolution Medicines daraxonrasib... More